ClinicalTrials.gg
TerminatedNCT07495813Updated Nov 17, 2026

A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease

A Phase 1 interventional study of RO7763505 and Placebo in Stable Coronary Artery Disease and Healthy Volunteers, sponsored by Hoffmann-La Roche. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
The development of RO7763505 for coronary artery disease has been discontinued.
Updated Nov 17, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Coronary Artery Disease with a site in Netherlands — 45 open to participants now, 66 under way, 5 of them phase 3. Coronary Artery Disease · Netherlands.

Enrollment
184th of 198
39 · median 348
Started
2026
with 6 others
Phase 1
7 of 283
none open now
Registered
280th of 283
by date

Among the 283 studies in Coronary Artery Disease with a site in Netherlands, this one is the 184th largest by enrollment of the 198 interventional ones that give a count, is one of 7 that started in 2026, is one of 7 in phase 1, and was the 280th registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

45 of the 283 studies in Coronary Artery Disease with a site in Netherlands are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in Netherlands, or all of them as a file.
02

Study summary

This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).

03

Conditions studied

  • Stable Coronary Artery Disease
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  • Healthy biologically male and female participants of nonchildbearing potential or with no findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgical history, vital signs, 12-lead (ECG), hematology, blood chemistry, serology, and urinalysis
  • No suspicion of cognitive impairment/dementia as judged by the Investigator

Part 2:

  • Myocardial infarction before the screening visit
  • Objective imaging evidence (coronary computed tomography [CT] angiography or invasive angiography) of coronary atherosclerosis Participants who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) are eligible if the procedure was done >6 months prior to screening
  • A diagnosis of stable CAD, defined as being on stable guideline-directed medical therapy (GDMT) if tolerated for at least 90 days prior to screening with no planned changes or scheduled interventions during the study
  • of \<= 450 milliseconds (ms) as determined by a single 12-lead ECG recording. If the initial ECG result of the triplicate is exclusionary, consecutive repeat ECG results must be within the acceptable limits. In participants with a stable bundle branch block where the QRS duration is > 120 ms, the QTcF will be calculated as: QTcF - (QRS - 100 ms)

Exclusion criteria

Exclusion Criteria:

Part 1:

  • Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
  • Vaccination within 28 days prior to Day 1 (non- including influenza vaccination are permitted 14 days prior to Day 1) or planned before the end of the study. Investigators are advised to review the immunization status of participants who are considered for treatment with RO7763505 and follow local/national guidance for adult vaccination against infectious disease as they deem relevant
  • Positive result on (HIV)-1 and HIV-2, virus (HBV) (either hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]), virus (HCV) antibody test, or tuberculosis (TB)

Part 2:

  • Individuals with (NYHA) Class III or IV heart failure
  • Known or suspected state
  • Treatment with any therapy within 28 days or within five drug-elimination half-lives (whichever is longer; or longer than either if required by local regulations; if the half-life is unknown, the 90-day period applies) prior to Day 1, calculated from the day of the follow-up from the previous study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Part 1: SAD, MAD, and Food Effect in Healthy Participants

    Healthy participants will receive RO7763505 or matching placebo.

    Drug: RO7763505 · Drug: Placebo

  • Experimental
    Part 2: In Stable CAD Participants

    Participants with stable CAD will receive RO7763505 or matching placebo.

    Drug: RO7763505 · Drug: Placebo

Interventions

  • DrugRO7763505

    Participants will receive RO7763505 as per the schedule described in the protocol.

  • DrugPlacebo

    Participants will receive matching placebo as per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Part 1a and Part 1b: Percentage of Participants With Adverse Events (AEs)

    Time frame: Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks

  2. Part 1c: Plasma Concentration of RO7763505 in Fasted and fed State

    Time frame: Approximately up to 3 Weeks

  3. Part 2: Percentage of Participants With AEs

    Time frame: Approximately up to 6 Weeks

Secondary outcomes

  1. Part 1a and Part 1b: Plasma Concentration of RO7763505 and its Metabolites

    Time frame: Part 1a: Approximately up to 2 Weeks; Part 1b: Approximately up to 3 Weeks

  2. Part 1a and Part 1b: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated Interleukin-1 Beta ( IL-1β)

    Time frame: Part 1a: Baseline, Approximately up to 2 Weeks; Part 1b: Baseline, Approximately up to 3 Weeks

  3. Part 1c: Percentage of Participants With AEs

    Time frame: Approximately up to 3 Weeks

  4. Part 2: Plasma Concentration of RO7763505 and its Metabolites

    Time frame: Approximately up to 6 Weeks

  5. Part 2: Percentage Change From Baseline in Inhibition of Ex Vivo-Stimulated IL-1β

    Time frame: Baseline, Approximately up to 6 Weeks

07

Study locations

1 site
  • ICON Plc (LPRA) - Netherlands
    Groningen, 9728 NZ, Netherlands
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Aug 2026, 4 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Aug 2026 and completion Oct 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 27, 2026
StartActual
Mar 31, 2026
Primary completionActual
Aug 20, 2026was Oct 2026
CompletionActual
Aug 20, 2026was Oct 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The development of RO7763505 for coronary artery disease has been discontinued.
changed Nov 17, 2026
Primary completion
Oct 30, 2026→Aug 20, 2026 (actual)
Nov 17, 2026
Study completion
Oct 30, 2026→Aug 20, 2026 (actual)
Nov 17, 2026
Enrollment
196 (estimated)→39 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Terminated
    Why stopped The development of RO7763505 for coronary artery disease has been discontinued.
    Primary completion Oct 30, 2026→Aug 20, 2026 (now actual)
    Study completion Oct 30, 2026→Aug 20, 2026 (now actual)
    Enrollment 196 (estimated)→39 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07495813
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Mar 31, 2026
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update
Nov 17, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion